Study on Oral Drugs for Hypertension in Pregnancy

Introduction to Hypertension in Pregnancy

Researchers have recently explored the effectiveness of three oral medications for treating hypertension during pregnancy. This condition is one of the most prevalent medical issues faced by women in this critical period, affecting approximately ten percent of pregnancies. Various forms of hypertension pose risks to both the mother and the baby, increasing the likelihood of additional health concerns such as chronic kidney disease, type 2 diabetes, obesity, and premature cardiovascular complications.

Current Treatment Options

While intravenous (IV) medications are the most common approach to managing hypertension during pregnancy due to their rapid blood pressure regulation capabilities, they also carry risks of excessive blood pressure reduction. Moreover, the administration of IV drugs necessitates careful monitoring of both mother and baby, which can be resource-intensive. This is particularly challenging in low- or middle-income countries, where access to IV treatments is limited due to the need for specialized equipment and trained personnel.

Research Overview

To address this issue, researchers conducted a study to evaluate the safety and effectiveness of three widely available oral antihypertensive drugs compared to standard IV treatments in public hospitals in India. The findings were published in The Lancet. The study took place from April 2015 to August 2017 in two public hospitals in Nagpur, India, involving 894 women who were at least 28 weeks pregnant and diagnosed with severe hypertension requiring treatment.

Methodology

Participants were randomly assigned to one of three groups, each receiving a different medication: Nifedipine, Labetalol, or Methyldopa. In the Nifedipine and Labetalol groups, healthcare providers administered an initial pre-determined dose, with additional doses given based on blood pressure readings. Conversely, the Methyldopa group received a single dose without further adjustments. Blood pressure and pulse were monitored every 20 minutes, with additional health assessments and fetal heart rate monitoring occurring at specified intervals. Upon discharge, participants were interviewed regarding their pain levels, side effects, and overall satisfaction with the treatment.

Results

Six months into the study, the Methyldopa group size was increased based on findings from another study suggesting its greater efficacy. After analysis, results indicated that 84% of women taking Nifedipine experienced reduced blood pressure without the need for additional treatment. Labetalol followed closely with a 77% success rate, while Methyldopa showed a 76% improvement. Notably, patients on Nifedipine required fewer follow-up doses but reported more frequent headaches, increased heart rates, and higher ICU admissions compared to other groups.

Conclusion

The study’s findings suggest that oral medications can serve as effective treatments for hypertension during pregnancy. The research team advocates for the use of Nifedipine and Labetalol in managing severe hypertension, particularly for patients who may lack access to conventional IV therapies.

About the Author

This article was written by Rebecca K. Blankenship.

Related Topics

– How Does a Mexican Diet Affect the Risk of Hypertension?
– Practical Approaches to Treating Hypertension
– The Connection Between Smoking, Hypertension, Diabetes, and Obesity
– The Relationship Between Gum Disease and Hypertension
– Understanding Hypertension: The Silent Killer

Reference

Easterling T, Mundle S, Bracken H et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. The Lancet. 2019;394(10203):1011-1021. doi:10.1016/s0140-6736(19)31282-6.